vs
Side-by-side financial comparison of Fabrinet (FN) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Fabrinet is the larger business by last-quarter revenue ($1.1B vs $783.7M, roughly 1.4× Insulet Corporation). Insulet Corporation runs the higher net margin — 13.0% vs 9.9%, a 3.0% gap on every dollar of revenue. On growth, Fabrinet posted the faster year-over-year revenue change (35.9% vs 31.2%). Insulet Corporation produced more free cash flow last quarter ($48.2M vs $-5.3M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 24.4%).
FabrinetFNEarnings & Financial Report
Below is a list of companies having stocks that are included in the S&P MidCap 400 stock market index. The index, maintained by S&P Dow Jones Indices, comprises the common stocks of 400 mid-cap, mostly American, companies. Although called the S&P 400, the index sometimes contains more than 400 stocks when it includes two or more share classes of stock from one of its component companies.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
FN vs PODD — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $783.7M |
| Net Profit | $112.6M | $101.6M |
| Gross Margin | 12.2% | 72.6% |
| Operating Margin | 10.1% | 18.7% |
| Net Margin | 9.9% | 13.0% |
| Revenue YoY | 35.9% | 31.2% |
| Net Profit YoY | 30.0% | 0.9% |
| EPS (diluted) | $3.11 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $783.7M | ||
| Q3 25 | $978.1M | $706.3M | ||
| Q2 25 | $909.7M | $649.1M | ||
| Q1 25 | $871.8M | $569.0M | ||
| Q4 24 | $833.6M | $597.5M | ||
| Q3 24 | $804.2M | $543.9M | ||
| Q2 24 | $753.3M | $488.5M | ||
| Q1 24 | $731.5M | $441.7M |
| Q4 25 | $112.6M | $101.6M | ||
| Q3 25 | $95.9M | $87.6M | ||
| Q2 25 | $87.2M | $22.5M | ||
| Q1 25 | $81.3M | $35.4M | ||
| Q4 24 | $86.6M | $100.7M | ||
| Q3 24 | $77.4M | $77.5M | ||
| Q2 24 | $81.1M | $188.6M | ||
| Q1 24 | $80.9M | $51.5M |
| Q4 25 | 12.2% | 72.6% | ||
| Q3 25 | 11.9% | 72.2% | ||
| Q2 25 | 12.2% | 69.7% | ||
| Q1 25 | 11.7% | 71.9% | ||
| Q4 24 | 12.1% | 72.1% | ||
| Q3 24 | 12.3% | 69.3% | ||
| Q2 24 | 12.3% | 67.7% | ||
| Q1 24 | 12.4% | 69.5% |
| Q4 25 | 10.1% | 18.7% | ||
| Q3 25 | 9.6% | 16.7% | ||
| Q2 25 | 9.8% | 18.7% | ||
| Q1 25 | 9.0% | 15.6% | ||
| Q4 24 | 9.5% | 18.3% | ||
| Q3 24 | 9.6% | 16.2% | ||
| Q2 24 | 9.7% | 11.2% | ||
| Q1 24 | 9.7% | 12.9% |
| Q4 25 | 9.9% | 13.0% | ||
| Q3 25 | 9.8% | 12.4% | ||
| Q2 25 | 9.6% | 3.5% | ||
| Q1 25 | 9.3% | 6.2% | ||
| Q4 24 | 10.4% | 16.9% | ||
| Q3 24 | 9.6% | 14.2% | ||
| Q2 24 | 10.8% | 38.6% | ||
| Q1 24 | 11.1% | 11.7% |
| Q4 25 | $3.11 | $1.42 | ||
| Q3 25 | $2.66 | $1.24 | ||
| Q2 25 | $2.41 | $0.32 | ||
| Q1 25 | $2.25 | $0.50 | ||
| Q4 24 | $2.38 | $1.38 | ||
| Q3 24 | $2.13 | $1.08 | ||
| Q2 24 | $2.22 | $2.59 | ||
| Q1 24 | $2.21 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $960.8M | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | $2.2B | $1.5B |
| Total Assets | $3.3B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $960.8M | — | ||
| Q3 25 | $968.8M | — | ||
| Q2 25 | $934.2M | — | ||
| Q1 25 | $950.7M | — | ||
| Q4 24 | $934.6M | — | ||
| Q3 24 | $908.9M | — | ||
| Q2 24 | $858.6M | — | ||
| Q1 24 | $794.0M | — |
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.1B | $1.4B | ||
| Q2 25 | $2.0B | $1.5B | ||
| Q1 25 | $1.9B | $1.3B | ||
| Q4 24 | $1.8B | $1.2B | ||
| Q3 24 | $1.8B | $1.1B | ||
| Q2 24 | $1.7B | $998.4M | ||
| Q1 24 | $1.7B | $790.7M |
| Q4 25 | $3.3B | $3.2B | ||
| Q3 25 | $3.0B | $3.0B | ||
| Q2 25 | $2.8B | $3.5B | ||
| Q1 25 | $2.6B | $3.5B | ||
| Q4 24 | $2.5B | $3.1B | ||
| Q3 24 | $2.4B | $3.0B | ||
| Q2 24 | $2.3B | $2.9B | ||
| Q1 24 | $2.2B | $2.6B |
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 1.72× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.3M | $183.3M |
| Free Cash FlowOCF − Capex | $-5.3M | $48.2M |
| FCF MarginFCF / Revenue | -0.5% | 6.2% |
| Capex IntensityCapex / Revenue | 4.6% | 17.2% |
| Cash ConversionOCF / Net Profit | 0.41× | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $102.3M | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $46.3M | $183.3M | ||
| Q3 25 | $102.6M | $125.7M | ||
| Q2 25 | $55.1M | $196.5M | ||
| Q1 25 | $74.2M | $63.8M | ||
| Q4 24 | $115.9M | $147.7M | ||
| Q3 24 | $83.2M | $98.5M | ||
| Q2 24 | $83.1M | $96.5M | ||
| Q1 24 | $100.9M | $87.6M |
| Q4 25 | $-5.3M | $48.2M | ||
| Q3 25 | $57.3M | $100.1M | ||
| Q2 25 | $4.7M | $177.9M | ||
| Q1 25 | $45.7M | $51.5M | ||
| Q4 24 | $94.0M | $94.1M | ||
| Q3 24 | $62.9M | $71.8M | ||
| Q2 24 | $70.4M | $74.0M | ||
| Q1 24 | $87.3M | $65.5M |
| Q4 25 | -0.5% | 6.2% | ||
| Q3 25 | 5.9% | 14.2% | ||
| Q2 25 | 0.5% | 27.4% | ||
| Q1 25 | 5.2% | 9.1% | ||
| Q4 24 | 11.3% | 15.7% | ||
| Q3 24 | 7.8% | 13.2% | ||
| Q2 24 | 9.3% | 15.1% | ||
| Q1 24 | 11.9% | 14.8% |
| Q4 25 | 4.6% | 17.2% | ||
| Q3 25 | 4.6% | 3.6% | ||
| Q2 25 | 5.5% | 2.9% | ||
| Q1 25 | 3.3% | 2.2% | ||
| Q4 24 | 2.6% | 9.0% | ||
| Q3 24 | 2.5% | 4.9% | ||
| Q2 24 | 1.7% | 4.6% | ||
| Q1 24 | 1.9% | 5.0% |
| Q4 25 | 0.41× | 1.80× | ||
| Q3 25 | 1.07× | 1.43× | ||
| Q2 25 | 0.63× | 8.73× | ||
| Q1 25 | 0.91× | 1.80× | ||
| Q4 24 | 1.34× | 1.47× | ||
| Q3 24 | 1.07× | 1.27× | ||
| Q2 24 | 1.02× | 0.51× | ||
| Q1 24 | 1.25× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FN
| Optical Communications | $832.6M | 73% |
| Non Optical Communications | $300.3M | 27% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
